Solstice Neurosciences Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35.7M
Solstice Neurosciences General Information
Description
Owner and operator of a biopharmaceutical company. The company engages in the development, manufacture, marketing, and sale of biopharmaceutical products. Its products include Myobloc/NeuroBloc, a botulinum toxin type B injectable solution for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and pain associated with cervical dystonia. It also offers reimbursement support, product support, and medical information access services, as well as operates a MYOBLOC University, an online, self-study resource that incorporates learning technology for physicians.
Contact Information
Website
www.solsticeneuro.comCorporate Office
- 4010 Dupont Circle
- Suite L-07
- Louisville, KY 40207
- United States
Corporate Office
- 4010 Dupont Circle
- Suite L-07
- Louisville, KY 40207
- United States
Solstice Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 06-Aug-2010 | $35.7M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series B) | 08-Nov-2006 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 01-Jul-2005 | $8M | $8M | Completed | Product Development |
Solstice Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B |
Solstice Neurosciences Patents
Solstice Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100112006-A1 | Compositions of activated botulinum holotoxin type b (150 kd) | Inactive | 03-Nov-2008 | ||
| US-20100112005-A1 | Compositions of activated botulinum toxin type b | Inactive | 03-Nov-2008 | ||
| US-20100034854-A1 | Compositions of activated botulinum holotoxin type b (150 kd) | Inactive | 05-Aug-2008 | ||
| US-20120238504-A1 | Stable formulations of botulinum toxin in hydrogels | Inactive | 11-Sep-1998 | ||
| US-20140302008-A1 | Stable formulations of botulinum toxin in hydrogels | Inactive | 11-Sep-1998 | A61K38/4893 |
Solstice Neurosciences Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Highland Capital Management | Hedge Fund | Minority | ||
| Morgan Stanley Expansion Capital | Growth/Expansion | Minority | ||
| Oxford Bioscience Partners | Venture Capital | Minority | ||
| Patricia Industries | PE/Buyout | Minority | ||
| Thomas McNerney & Partners | Venture Capital | Minority |
Solstice Neurosciences FAQs
-
When was Solstice Neurosciences founded?
Solstice Neurosciences was founded in 2004.
-
Where is Solstice Neurosciences headquartered?
Solstice Neurosciences is headquartered in Louisville, KY.
-
What industry is Solstice Neurosciences in?
Solstice Neurosciences’s primary industry is Pharmaceuticals.
-
Is Solstice Neurosciences a private or public company?
Solstice Neurosciences is a Private company.
-
What is the current valuation of Solstice Neurosciences?
The current valuation of Solstice Neurosciences is .
-
What is Solstice Neurosciences’s current revenue?
The current revenue for Solstice Neurosciences is .
-
How much funding has Solstice Neurosciences raised over time?
Solstice Neurosciences has raised $93M.
-
Who are Solstice Neurosciences’s investors?
Highland Capital Management, Morgan Stanley Expansion Capital, Oxford Bioscience Partners, Patricia Industries, and Thomas McNerney & Partners have invested in Solstice Neurosciences.
-
When was Solstice Neurosciences acquired?
Solstice Neurosciences was acquired on 06-Aug-2010.
-
Who acquired Solstice Neurosciences?
Solstice Neurosciences was acquired by US WorldMeds.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
